Literature DB >> 21495862

Liver enzymes, type 2 diabetes, and metabolic syndrome in middle-aged, urban Chinese men.

Raquel Villegas1, Yong-Bing Xiang, Tom Elasy, Qiuyin Cai, Wanghong Xu, Honglan Li, Sergio Fazio, Macrae F Linton, David Raiford, Wei Zheng, Xiao Ou Shu.   

Abstract

BACKGROUND: We examined associations between elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) with physical activity and obesity measures in middle-aged urban Chinese men. The associations between elevated aminotransferases with impaired fasting glucose, newly diagnosed type 2 diabetes (T2D), and metabolic syndrome were also evaluated in this population.
METHODS: The study included 3,978 urban Chinese men 40-74 years of age from a population-based cohort study, the Shanghai Men's Health Study, who were free of T2D at baseline and had provided fasting blood samples. Elevated AST and ALT levels were defined as >40 U/L. Anthropometric measurements and information on lifestyle factors and disease history were collected by in-person interviews.
RESULTS: A total of 11.13% and 5.85% study participants had elevated serum ALT and AST levels, respectively. Both body mass index (BMI) and waist-to-hip ratio (WHR) were positively associated with elevated ALT and AST. We found stronger associations between ALT and BMI/WHR than between AST and BMI/WHR. Physical activity was inversely associated with ALT and AST, but the association was attenuated after adjustment for BMI and WHR. Elevated serum aminotransferase levels were associated with T2D and metabolic syndrome.
CONCLUSIONS: In this representative sample of middle-aged Chinese men, elevated ALT and AST were associated with a prevalence of metabolic syndrome and T2D. These findings suggest that the relationship between obesity and T2D might involve liver injury. Physical activity might reduce the levels of ALT and AST, probably mediated through weight reduction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21495862      PMCID: PMC3142636          DOI: 10.1089/met.2011.0016

Source DB:  PubMed          Journal:  Metab Syndr Relat Disord        ISSN: 1540-4196            Impact factor:   1.894


  29 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Compendium of physical activities: an update of activity codes and MET intensities.

Authors:  B E Ainsworth; W L Haskell; M C Whitt; M L Irwin; A M Swartz; S J Strath; W L O'Brien; D R Bassett; K H Schmitz; P O Emplaincourt; D R Jacobs; A S Leon
Journal:  Med Sci Sports Exerc       Date:  2000-09       Impact factor: 5.411

3.  High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes.

Authors:  Barbora Vozarova; Norbert Stefan; Robert S Lindsay; Aramesh Saremi; Richard E Pratley; Clifton Bogardus; P Antonio Tataranni
Journal:  Diabetes       Date:  2002-06       Impact factor: 9.461

4.  Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents.

Authors:  Hye Soon Park; Jee Hye Han; Kyung Mook Choi; Seon Mee Kim
Journal:  Am J Clin Nutr       Date:  2005-11       Impact factor: 7.045

5.  The associations of physical activity and adiposity with alanine aminotransferase and gamma-glutamyltransferase.

Authors:  Debbie A Lawlor; Naveed Sattar; George Davey Smith; Shah Ebrahim
Journal:  Am J Epidemiol       Date:  2005-06-01       Impact factor: 4.897

6.  Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study.

Authors:  Naveed Sattar; Olga Scherbakova; Ian Ford; Denis St J O'Reilly; Adrian Stanley; Ewan Forrest; Peter W Macfarlane; Chris J Packard; Stuart M Cobbe; James Shepherd
Journal:  Diabetes       Date:  2004-11       Impact factor: 9.461

7.  Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients.

Authors:  S Daniel; T Ben-Menachem; G Vasudevan; C K Ma; M Blumenkehl
Journal:  Am J Gastroenterol       Date:  1999-10       Impact factor: 10.864

8.  Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study.

Authors:  Monica Nannipieri; Clicerio Gonzales; Simona Baldi; Rosalinda Posadas; Ken Williams; Steven M Haffner; Michael P Stern; Ele Ferrannini
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

9.  Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study.

Authors:  Anthony J G Hanley; Ken Williams; Andreas Festa; Lynne E Wagenknecht; Ralph B D'Agostino; Judy Kempf; Bernard Zinman; Steven M Haffner
Journal:  Diabetes       Date:  2004-10       Impact factor: 9.461

10.  Metabolic syndrome and ALT: a community study in adult Koreans.

Authors:  S-K Jeong; H-S Nam; J-A Rhee; J-H Shin; J-M Kim; K-H Cho
Journal:  Int J Obes Relat Metab Disord       Date:  2004-08
View more
  10 in total

1.  Consumption of extra-virgin olive oil rich in phenolic compounds improves metabolic control in patients with type 2 diabetes mellitus: a possible involvement of reduced levels of circulating visfatin.

Authors:  C Santangelo; C Filesi; R Varì; B Scazzocchio; T Filardi; V Fogliano; M D'Archivio; C Giovannini; A Lenzi; S Morano; R Masella
Journal:  J Endocrinol Invest       Date:  2016-06-25       Impact factor: 4.256

2.  Longitudinal association of obesity, metabolic syndrome and diabetes with risk of elevated aminotransferase levels in a cohort of Mexican health workers.

Authors:  Yvonne N Flores; Allyn Auslander; Catherine M Crespi; Michael Rodriguez; Zuo-Feng Zhang; Francisco Durazo; Jorge Salmerón
Journal:  J Dig Dis       Date:  2016-05       Impact factor: 2.325

3.  Alanine aminotransferase within reference range is associated with metabolic syndrome in middle-aged and elderly Chinese men and women.

Authors:  Xuebing Zhang; Yiming Mu; Wenhua Yan; Jianming Ba; Hongmei Li
Journal:  Int J Environ Res Public Health       Date:  2014-12-10       Impact factor: 3.390

4.  Presence of Concurrent Derangements of Liver Function Tests in Type 2 Diabetes and Their Relationship with Glycemic Status: A Retrospective Observational Study from Meghalaya.

Authors:  Kaustubh Bora; Meghna Borah; Happy Chutia; Chandan Kumar Nath; Dulmoni Das; Alice Abraham Ruram
Journal:  J Lab Physicians       Date:  2016 Jan-Jun

5.  Metabolic Syndrome and Serum Liver Enzymes in the General Chinese Population.

Authors:  Shuang Chen; Xiaofan Guo; Shasha Yu; Ying Zhou; Zhao Li; Yingxian Sun
Journal:  Int J Environ Res Public Health       Date:  2016-02-17       Impact factor: 3.390

6.  Exendin-4 protects mice from D-galactose-induced hepatic and pancreatic dysfunction.

Authors:  Akram Ahangarpour; Ali Akbar Oroojan; Mohammad Badavi
Journal:  Pathobiol Aging Age Relat Dis       Date:  2017-12-26

7.  Association between liver function and metabolic syndrome in Chinese men and women.

Authors:  Sen Wang; Jie Zhang; Li Zhu; Linlin Song; Zhaowei Meng; Qiang Jia; Xue Li; Na Liu; Tianpeng Hu; Pingping Zhou; Qing Zhang; Li Liu; Kun Song; Qiyu Jia
Journal:  Sci Rep       Date:  2017-03-20       Impact factor: 4.379

8.  Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal.

Authors:  Bashu Dev Pardhe; Shreena Shakya; Anjeela Bhetwal; Jennifer Mathias; Puspa Raj Khanal; Roshan Pandit; Jyotsna Shakya; Hari Om Joshi; Sujan Babu Marahatta
Journal:  BMC Gastroenterol       Date:  2018-07-06       Impact factor: 3.067

9.  AST-to-ALT ratio in the first trimester and the risk of gestational diabetes mellitus.

Authors:  Rongjing An; Shujuan Ma; Na Zhang; Huijun Lin; Tianyu Xiang; Mengshi Chen; Hongzhuan Tan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-29       Impact factor: 6.055

10.  Liver enzymes and metabolic syndrome: a large-scale case-control study.

Authors:  Lu Zhang; Xiangyu Ma; Zhi Jiang; Kejun Zhang; Mengxuan Zhang; Yafei Li; Xiaolan Zhao; Hongyan Xiong
Journal:  Oncotarget       Date:  2015-09-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.